Beam Therapeutics (BEAM) News
NASDAQ: BEAMHealth CareBiotechnology: Biological Products (No Diagnostic Substances)USD
20.90-0.04 (-0.19%)
At close: Nov 20, 4:00 PM ET · Delayed 15 min
BEAM news summary
We found 8 recent headlines mentioning Beam Therapeutics (BEAM): 0 in the past week and 7 in the past 30 days, most often from Nasdaq, GlobeNewswire, Seeking Alpha. For price context, BEAM is down 0.19% at $20.90. The most recent story, "Weekly Buzz: LLY, JNJ Win FDA Nod; SION, NNOX, Cut Jobs; PFE, ARGX Strike Deals", was published by Nasdaq on Nov 13, 2026.
Headlines link to the original publishers. MetaCap does not republish third-party articles.
Summary generated from market data by MetaCap's automated system. Methodology
Latest Beam Therapeutics headlines
- Weekly Buzz: LLY, JNJ Win FDA Nod; SION, NNOX, Cut Jobs; PFE, ARGX Strike Deals(RTTNews) - This week's biotech roundup features a series of regulatory approvals across obesity, stroke prevention, oncology, and medical devices, alongside workforce reductions and cost-cutting…NasdaqAMGN, ARGX, AZN, BEAM
- Beam Therapeutics Inc. Reports Third Quarter 2026 Financial Results and Clinical ProgressBeam Therapeutics Inc. reported its financial results for the third quarter ended September 30, 2026. The company ended the quarter with $1.0 billion in cash, cash equivalents and marketable…Nasdaq
- Beam Therapeutics Inc. (BEAM) Reports Q3 Loss, Misses Revenue EstimatesBeam Therapeutics (BEAM) delivered earnings and revenue surprises of -9.40% and -97.23%, respectively, for the quarter ended September 2026. Do the numbers hold clues to what lies ahead for the stock?NasdaqBEAM, TWST
- Beam Therapeutics GAAP EPS of -$1.28 misses by $0.13, revenue of $0.31MSeeking Alpha
- Beam Therapeutics Reports Third Quarter 2026 Financial Results and Highlights Clinical Progress Across Base Editing PortfolioUpdated BEAM-302 Phase 1/2 Clinical Data Presented at ERS Demonstrated Durable Increases in Functional AAT and Reductions in Mutant Z-AAT; Completion of Dosing in the Global Pivotal Cohort Expected…GlobeNewswire
- 3 Promising Genomics Stocks to Add to Your Portfolio NowGenomics and synthetic biology are transforming healthcare through precision medicine and gene editing, putting ILMN, QURE and TXG in focus as the markets expand.NasdaqILMN, QURE, TXG, BEAM
- Beam Therapeutics Reports Initial Clinical Data from Phase 1/2 Trial of BEAM-301, Demonstrating Proof of Concept for Genetic Correction in Glycogen Storage Disease Type Ia (GSDIa) at ESGCT 33rd Annual CongressIn the 40 mg Cohort, Two Patients Achieved 15 Hours of Controlled Fasting, Improvements in Glucose Control and No Longer Required Starch Supplementation Following TreatmentGlobeNewswire
- Cathie Wood Keeps Buying Beam Therapeutics on the Dip. Should You Follow Her Lead?Key PointsCathie Wood owns Beam shares worth roughly $220 million, at the stock's current price.NasdaqBEAM, LLY, PFE, ARKG